齐帕尔蒂尼布-一种新的治疗机会,用于非小细胞肺癌,具有EXON 20插入和不常见的EGFR突变
Wolfram C M Dempke1, Klaus Fenchel2, Niels Reinmuth3
1University Hospital, LMU Munich, Grosshadern Campus, 81377 Munich, Germany.
Cancers
|January 28, 2026
概括
齐帕尔蒂尼布对非小细胞肺癌 (NSCLC) 患者具有不常见的EGFR突变和外显子20插入有希望. 目前正在进行的试验正在评估其在各种环境中的有效性,包括一线治疗和大脑转移.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 非小细胞肺癌 (NSCLC) 的死亡率很高,EGFR的改变推动了治疗的进展.
- 在NSCLC中,不常见的EGFR突变和外显子20插入呈现出不良预后,需要新的治疗方法.
- 目前的EGFR氨酸激酶抑制剂 (TKI) 对这些特定变化的疗效有限.
研究的目的:
- 评估一项新型EGFR TKI-Zipalertinib对非常见EGFR突变和NSCLC中外20插入的疗效.
- 评估齐帕尔蒂尼布在各种临床环境中的活性,包括一线治疗,大脑转移和辅助治疗.
- 探索齐帕尔蒂尼布单独或组合在NSCLC治疗环境中的作用.
主要方法:
- 开发了Zipalertinib,一种口服,不可逆转的EGFR TKI,具有独特的pyrrolopyrimidine结构.
- 临床前活动的评估是针对经典和不常见的EGFR突变,包括外20插入.
- 临床活性正在多个NSCLC试验中进行评估 (REZILIENT 1-4),包括一线治疗和大脑转移.
主要成果:
- 齐帕尔蒂尼布对经典EGFR突变 (del19,L858R) 和一些不常见的突变 (T790M,G719X,S768I,L861Q) 显示出活性.
- 该化合物在具有EGFR外基子20插入的NSCLC细胞中表现出主要活性.
- 来自REZILIENT试验的初步临床数据表明,在患有不常见突变,外20插入和大脑转移的患者中,该药物具有显著的活性.
结论:
- 齐帕尔蒂尼布是一种有前途的新型EGFR TKI,用于具有具有具有挑战性突变的NSCLC患者,特别是对外子20插入.
- 目前正在进行的临床试验对于确定齐帕尔蒂尼布在一线,组合和辅助疗法中的作用至关重要.
- 需要进一步的证据来确定与其他药物和化疗组合相比,齐帕尔蒂尼布的治疗影响.
相关概念视频
Cancers Originate from Somatic Mutations in a Single Cell
14.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Mutations
94.4K
Overview
94.4K
Mutations
44.5K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
Exon Recombination
4.2K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon...
Exon shuffling follows “splice frame rules.” Each exon...
4.2K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Viral Mutations
39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K


